Health-related quality of life in the randomised KEYNOTE-002 study of pembrolizumab versus chemotherapy in patients with ipilimumab-refractory melanoma-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Health-related quality of life in the randomised KEYNOTE-002 study of pembrolizumab versus chemotherapy in patients with ipilimumab-refractory melanoma

Published:2016-11 Issue: Volume:67 Page:46-54
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Schadendorf Dirk^ORCID,Dummer Reinhard,Hauschild Axel,Robert Caroline,Hamid Omid,Daud Adil,van den Eertwegh Alfons,Cranmer Lee,O'Day Steven,Puzanov Igor,Schachter Jacob,Blank Christian,Salama April,Loquai Carmen,Mehnert Janice M.,Hille Darcy,Ebbinghaus Scot,Kang S. Peter,Zhou Wei,Ribas Antoni

Funder

Merck & Co., Inc. (Kenilworth, NJ, USA)

Merck & Co., Inc.

Amgen

Bristol-Myers Squibb

Novartis

Roche/Genentech

Roche

GlaxoSmithKline

Celgene

Eisai

Merck Serono

Reata

Genentech

Celldex

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference23 articles.

1. Checkpoint blockade in cancer immunotherapy;Korman;Adv Immunol,2006

2. PD-1:PD-L inhibitory pathway affects both CD4(+) and CD8(+) T cells and is overcome by IL-2;Carter;Eur J Immunol,2002

3. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation;Freeman;J Exp Med,2000

4. PD-L2 is a second ligand for PD-1 and inhibits T cell activation;Latchman;Nat Rev Immunol,2001

5. PD-1 as a potential target in cancer therapy;McDermott;Cancer Med,2013

Cited by 78 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Understanding quality of life issues in patients with advanced melanoma: Phase 1 and 2 in the development of the EORTC advanced melanoma module;European Journal of Cancer;2024-08

2. Health-related quality-of-life analysis from KEYNOTE-590: pembrolizumab plus chemotherapy versus chemotherapy for advanced esophageal cancer;The Oncologist;2024-05-30

3. Systemic Treatment of Melanoma;Rook's Textbook of Dermatology;2024-03-19

4. Immune checkpoint inhibitors in metastatic melanoma therapy (Review);Medicine International;2024-02-09

5. The Symptom Experience of Patients with Advanced Melanoma Undergoing Immune Checkpoint Inhibitor (ICI) Therapy;Seminars in Oncology Nursing;2024-02

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3